Patients, employers, and taxpayers in the United States face the highest pharmaceutical prices in the world.
The U.S. system yields brand name drug prices that are nearly three times as high as prices in Organization for Economic Co-operation and Development (OECD) comparison countries, even after accounting for rebates. In 2022, among all OECD countries, the U.S. made up approximately 60% of sales revenues, but only 24% of the volume.
